Bristol-Myers Squibb(US:BMY) Xin Lang Cai Jing·2025-06-30 23:58Core Insights - Bristol-Myers Squibb (BMS) has implemented a series of layoffs in Lawrenceville, New Jersey, totaling 1,223 employees since April 2024, with 874 of those occurring in 2025 alone, nearing an annual total of 900 layoffs [1][3][4] - The layoffs are part of a strategic restructuring plan aimed at achieving significant cost savings, with a target of $1.5 billion by the end of 2025 and an increased goal of $3.5 billion by 2027 [3][4] Layoff Implementation Schedule - The layoffs will be executed in phases, starting on September 25, 2025, and concluding by January 15, 2026 [2] - It remains uncertain whether the layoffs will affect the commercial and late-stage R&D teams, which are critical to BMS's operations [2] Cost Reduction Strategy - BMS's layoffs are part of a broader cost-cutting strategy initiated in April 2024, with an initial plan to cut 2,200 jobs by the end of 2024 [3] - The company reported a 6% year-over-year decline in Q1 2025 revenue, totaling $11.2 billion, with U.S. market revenue down 7% to $7.9 billion, yet it remains optimistic about its annual revenue forecast, adjusting it to a range of $45.8 billion to $46.8 billion [3] Historical Layoff Trends - In 2024, BMS conducted three rounds of layoffs in Lawrenceville, totaling 349 employees, while 2025 has seen an accelerated pace with significant layoffs in February and May [4] - The ongoing layoffs reflect a broader trend in the pharmaceutical industry, where companies are restructuring to focus on core therapeutic areas and innovation pipelines [4]